This is a longer runway than many people expect, which is exactly why it needs to be planned ahead
Industry forecasts from BCC Research similarly projects substantial long-term growth $268.4 billion by 2030 in the GLP-1 analogue market through the end of the decade
Advances in receptor de-orphanization, structural biology, and computational modeling have substantially reduced these barriers, warranting renewed evaluation of such systems
The cost of GLP-1 RAs remains a barrier, particularly in low- and middle-income countries
GLP-1 users saw a 44% reduction in hospitalizations due to stroke, heart attack and heart failure compared to the control group
They improve glycemic control by inducing glycosuria, osmotic diuresis, and reduced glucose-sodium proximal tubule reabsorption